Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors, Level of T Cell Subsets and Serum Tumor Markers

MA Dong-yang; GENG Liang; HU Yan-hui; CUI Qing-li; LIU Huai-min

doi:10.13422/j.cnki.syfjx.2017070173

您当前的位置：

首页 >

文章列表页 >

Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors, Level of T Cell Subsets and Serum Tumor Markers

更新时间：2024-01-04

- Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors, Level of T Cell Subsets and Serum Tumor Markers
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 7, Pages: 173-178(2017)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2017070173
  CLC： R734.2
- Published：2017
- 稿件说明：
移动端阅览
MA Dong-yang, GENG Liang, HU Yan-hui, et al. Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors, Level of T Cell Subsets and Serum Tumor Markers[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(7): 173-178.
DOI：

MA Dong-yang, GENG Liang, HU Yan-hui, et al. Effect of Kangliu Zengxiao Formula Combined with Gefitinib in Treating Elderly Non-small Cell Lung Cancer and on Inflammation Factors, Level of T Cell Subsets and Serum Tumor Markers[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(7): 173-178. DOI： 10.13422/j.cnki.syfjx.2017070173.

摘要

目的：探讨抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌及对患者炎症因子，T细胞亚群水平及血清肿瘤标志物影响。方法：选取郑州大学附属肿瘤医院肿瘤内科非小细胞肺癌Ⅳ期老年患者84例，患者或家属签字同意，积极配合此次研究，按随机数字表法分组，对照组患者（42例）予以单纯吉非替尼治疗，研究组患者（42例）予以吉非替尼联合抗瘤增效方治疗，观察并记录所有患者治疗前后生存质量、炎症因子及T细胞亚群水平，同时对比临床疗效及不良反应状况。结果：对照组有效率低于研究组（P<0.05）；与治疗前比较，两组患者治疗后生存质量、炎症因子及T细胞亚群水平均发生变化，研究组治疗后躯体功能，角色功能，社会功能，情绪功能评分高于对照组，研究组治疗后白细胞介素-2（interleukin-2，IL-2），白细胞介素-12（interleukin-12，IL-12）和γ-干扰素（interferon-γ，IFN-γ）水平高于对照组，研究组治疗后CD8+水平低于对照组，CD4+及CD4+/CD8+水平高于对照组（P<0.05）；治疗后，对照组血管内皮生长因子（vascular endothelial growth factor，VEGF）升高，治疗组VEGF下降（P<0.05）；与治疗前比较，两组患者癌胚抗原（carcinoembryonic antigen，CEA），糖抗原（carbohydrate antigen-125，CA125）及细胞角蛋白19片段21-1（cytokeratin 19 fragments，CYFRA21-1）差异无统计学意义，组间比较差异无统计学意义；两组患者不良反应较轻，无药物不良反应。结论：抗瘤增效方联合吉非替尼治疗老年非小细胞肺癌疗效确切，能提高生活质量及免疫功能。

Abstract

Objective: To investigate the effect of Kangliu Zengxiao formula combined with gefitinib in treating elderly non-small cell lung cancer and on inflammation factors

level of T cell subsets and serum tumor markers. Method: The 84 cases of elderly non-small cell lung cancer were selected

and the patients or their family members signed the informed consent toactively cooperate with the study. They were divided into 2 groups. The 42 patients in control group were treated with gefitinib alone

while the 42 patients in treatment group received Kangliu Zengxiao formula. Quality of life

inflammatory cytokines and T lymphocyte subsets

and the clinical efficacy and adverse reactions were observed and compared. Result: The control group was inferior to treatment group in effective rate(P<0.05). Compared with before treatment

survival quality

inflammatory cytokines and T cell subsets level changed in both groups. Compared with the control group

body function

role function

social function

emotional function score

levels of interleukin-2 (IL-2)

interleukin-12(IL-12) and interferon-γ(IFN-γ) were higher in treatment group

with lower CD8+ level

and CD4+ and CD4+/CD8+ levels were higher in control group(P<0.05). After treatment

vascular endothelial growth factor(VEGF) increase dinthe control group

whereas treatment group showed decreased VEGF (P<0.05). Compared with before treatment

the two groups showed no statistically significant difference in carcino embryonic antigen (CEA)

carbohydrate antigen-125(CA125) and cytokeratin 19 fragments(CYFRA21-1)

with no inter-group statistical significance. Adverse reactions in two groups were mild

with no adverse drug reaction. Conclusion: Kangliu Zengxiao formula combined with gefitinib in the treatment of elderly non-small cell lung cancer was effective

and can improve the life quality and immune function.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress to Attenuate Cisplatin Resistance in Non-small Cell Lung Cancer via Nrf2/ROS Pathway

Buzhong Yiqitang Regulates Endoplasmic Reticulum Stress via Nrf2/ROS/PERK/CHOP Signaling Pathway to Attenuate Cisplatin Resistance in NSCLC

Investigating Mechanism of Fritillariae Cirrhosae Bulbus Against Pulmonary Fibrosis Based on Spatial Metabolomics

Buzhong Yiqitang Regulates Apoptosis via Nrf2/ROS Pathway to Alleviate Cisplatin Resistance in A549/DDP Cells

Mechanism of PI3K/Akt/mTOR Signaling Pathway Against Non-small Cell Lung Cancer and Chinese Medicine Intervention： A Review

Related Author

YU Dan

MU Qirui

LI He

LIU Yuetong

HUANG Jingyi

GAO Yuan

LI He

LIU Yuetong

Related Institution

College of Integrated Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

College of Integrated Traditional Chinese and Western Medicine， Liaoning University of Traditional Chinese Medicine

TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province，Hospital of Chengdu University of TCM

College of Food and Biological Engineering， Chengdu University

Key Laboratory of Biological Evaluation of Traditional Chinese Medicine（TCM） Quality of National Administration of TCM，Sichuan Academy of Chinese Medicine Sciences

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰